ATLANTA, Aug. 23, 2006 (PRIMEZONE) -- OTC Stock Review and Amex Review have initiated coverage of Signalife, Inc. (AMEX:SGN), a breakthrough medical device company focused on the detection of cardiovascular disease through continuous ECG signal monitoring. Using its patented signal processing technology, Signalife designs and develops medical devices that improve the efficacy and reduce the costs of diagnostic testing and monitoring of ambulatory patients. Signalife's revolutionary, FDA-approved, patented 12-lead electrocardiograph (ECG) monitoring system, called Fidelity100, records high-quality ECG signals from ambulatory cardiac patients. The Fidelity100 addresses a critical need in the $400 billion cardiovascular market.
Signalife's technology allows a patient's ECG to be precisely monitored during everyday activities, capturing the most important information. Extensive and continuous cardiac data collected from patients can be stored and used as a baseline to detect abnormalities. This data facilitates improved diagnostic and preventive solutions for the physician as well as cost savings to health care providers and insurance companies. Cardiovascular disease is the leading cause of death in the world today with an estimated cost in 2006 of $403.1 billion. 40% of all U.S. hospital revenues are generated by cardiovascular disease and there are more than 100 million resting ECG's performed annually in the U.S. The industry will have a significant technological advance if clinical quality ECG's were recorded with clarity during patients' everyday activities.
The Fidelity100 Heart Monitor and Signalife's patented technology represent a major breakthrough in medical science that can impact hundreds of thousands of lives.
The complete report is available at http://www.otcstockreview.com/Files/SGN/SGN_Review.pdf.
View OTC Stock Review's complete coverage on Signalife, Inc. at http://www.otcstockreview.com/sgn.htm.
OTC Stock Review provides a comprehensive review of financial market coverage, specifically the microcap market, by newsletters, mutual funds, brokerage firm and independent research firms. OTC Stock Review defines the microcap segment of the equity market as companies with less than $250 million in market capitalization.
Please visit http://www.otcstockreview.com.
NOTE: The purpose of this release is to introduce the reader to OTCStockReview.com and Signalife, Inc. OTC Stock Review and Amex Review are not Registered Investment Advisors or Broker/Dealers. The information in this release is for informative purposes, not intended as investment advice, not an offer to buy or sell securities of the companies profiled, and is subject to change without notice. In keeping with Section 17b of the Securities Act of 1933, we advise you that OTC Stock Review has been compensated $7,500.00 by a third-party to perform investor relations services for Signalife, Inc. Officers, directors, and employees of OTC Stock Review may hold a long or short equity position of a profiled company and trade in these securities for their own accounts. Information is from public releases and cannot be guaranteed by OTC Stock Review. Companies profiled may carry a high investment risk; readers should review profiled companies thoroughly with their investment advisor, stockbroker, or other such professional. OTC Stock Review is not liable for any investment decisions by its readers or their advisors. Any analysis contained herein does not purport to be a complete analysis and readers are encouraged to obtain copies of the profiled Company's periodic reports filed with United States Securities and Exchange Commission which are generally available at http://www.sec.gov or http://www.sedar.com for Canadian companies. You can view our complete disclaimer at http://www.otcstockreview.com/disclaimer.htm.